FILSPARI's approval in FSGS creates a new standard of care and first-mover advantage in a rare disease with no prior approved treatments. Traders should monitor commercial ramp-up and potential pricing power, while watching for competitive responses. Consider this a major value inflection given the expanded addressable market.
TVTX drugs
TVTX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 14 $42.13entry
- T+1 · 7mo ago −2.80%α −3.58% · $40.95
- T+5 · 7mo ago −7.95%α −9.35% · $38.78
- T+20 · 6mo ago +3.28%α −3.02% · $43.51
- T+60 · 4mo ago +38.78%α +30.26% · $58.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Travere Therapeutics (TVTX) announced FDA approval of FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8+ with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This marks the first and only FDA-approved treatment for FSGS, expanding FILSPARI's label beyond IgA nephropathy.
Key Facts
- FDA approved FILSPARI for FSGS without nephrotic syndrome in patients aged 8 and older
- FILSPARI is the first and only FDA-approved treatment for FSGS
- Approval expands FILSPARI's label beyond IgA nephropathy into a second rare kidney disease
- Phase 3 DUPLEX study showed 48% reduction in proteinuria vs 27% for irbesartan in non-nephrotic FSGS patients
- Company estimates U.S. addressable population exceeds 30,000 individuals with FSGS without nephrotic syndrome
Financial Impact
Potential blockbuster expansion: FILSPARI now addresses >30,000 additional U.S. FSGS patients without nephrotic syndrome, significantly expanding its commercial opportunity beyond IgA nephropathy
Risk Factors
- Commercial execution risk in launching and marketing to a new patient population
- Potential payer reimbursement challenges for a high-cost rare disease drug
- Safety profile monitoring in broader patient population
- Future competition from emerging FSGS therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001438533-26-000032 |
| Document: 0001438533-26-000032-index-headers.html | 0001438533-26-000032 |
| Document: 0001438533-26-000032-index.html | 0001438533-26-000032 |
| Document: 0001438533-26-000032.txt | 0001438533-26-000032 |
Track record
21 reports on TVTX
8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
- Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
- Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
- Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
- Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers